NMRA Q1 2023 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

NMRANeumora Therapeutics, Inc. Common Stock

$586M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$39M

Net Income

-$36M

EPS (Diluted)

$-0.23

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$33M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$392M

Total Liabilities

$26M

Stockholders' Equity

$366M

Cash & Equivalents

$211M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$39M	-$43M	+9.4%
Net Income	-$36M	-$43M	+17.2%